The stock of Roka Bioscience Inc (NASDAQ:ROKA) is a huge mover today! About 999,277 shares traded hands or 1371.49% up from the average. Roka Bioscience Inc (NASDAQ:ROKA) has declined 16.33% since April 20, 2016 and is downtrending. It has underperformed by 20.89% the S&P500.
The move comes after 8 months positive chart setup for the $11.72 million company. It was reported on Nov, 22 by Barchart.com. We have $5.67 PT which if reached, will make NASDAQ:ROKA worth $937,600 more.
Roka Bioscience Inc (NASDAQ:ROKA) Ratings Coverage
Out of 3 analysts covering Roka Bioscience (NASDAQ:ROKA), 0 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 0 are positive. Roka Bioscience has been the topic of 7 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The rating was downgraded by Leerink Swann on Monday, March 7 to “Market Perform”. Leerink Swann maintained Roka Bioscience Inc (NASDAQ:ROKA) rating on Friday, August 14. Leerink Swann has “Outperform” rating and $4 price target. The stock of Roka Bioscience Inc (NASDAQ:ROKA) has “Hold” rating given on Tuesday, September 8 by Zacks. The rating was downgraded by Zacks to “Hold” on Tuesday, August 25.
According to Zacks Investment Research, “Roka Bioscience, Inc. is a molecular diagnostics company. It is focused on developing and commercializing advanced testing solutions for the food safety testing market. Roka provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin-producing E. coli, and Listeria monocytogenes, as well as related consumable supplies. Roka Bioscience, Inc. is headquartered in Warren, New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.50, from 0.5 in 2016Q1. The ratio is positive, as 4 funds sold all Roka Bioscience Inc shares owned while 2 reduced positions. 1 funds bought stakes while 2 increased positions. They now own 11.75 million shares or 4.44% less from 12.30 million shares in 2016Q1.
Royal Savings Bank Of Canada has 0% invested in the company for 200 shares. Goldman Sachs Gp accumulated 0% or 10,577 shares. Bank & Trust Of America De last reported 0% of its portfolio in the stock. Cannell Peter B And accumulated 0% or 58,098 shares. Nea Mngmt Limited Liability Company reported 3.22 million shares or 0.1% of all its holdings. Vanguard Gp has invested 0% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA). Weiss Multi accumulated 0% or 54,675 shares. The Ontario – Canada-based Manufacturers Life Ins Com The has invested 0% in Roka Bioscience Inc (NASDAQ:ROKA). The California-based Blackrock Fund has invested 0% in Roka Bioscience Inc (NASDAQ:ROKA). Renaissance Technology Limited Liability, a New York-based fund reported 55,400 shares. Blackrock Inc holds 0% of its portfolio in Roka Bioscience Inc (NASDAQ:ROKA) for 120 shares. Tpg Hldgs (Sbs) Advsr Inc last reported 0.02% of its portfolio in the stock. Orbimed Advsr Limited Liability Corporation holds 3.22 million shares or 0.02% of its portfolio. The California-based Wells Fargo & Company Mn has invested 0% in Roka Bioscience Inc (NASDAQ:ROKA). Drill Craig A holds 1.8% or 1.60M shares in its portfolio.
More notable recent Roka Bioscience Inc (NASDAQ:ROKA) news were published by: Prnewswire.com which released: “Roka Bioscience, Inc. Announces One-For-Ten Reverse Stock Split” on October 11, 2016, also Marketwatch.com with their article: “Roka Bioscience upgraded to outperform from market perform at Leerink Partners” published on July 17, 2014, Prnewswire.com published: “Roka Bioscience, Inc. Prices Private Placement of Preferred Stock and Warrants” on September 16, 2016. More interesting news about Roka Bioscience Inc (NASDAQ:ROKA) were released by: Prnewswire.com and their article: “Roka Bioscience Reports Third Quarter 2016 Financial Results” published on November 07, 2016 as well as Prnewswire.com‘s news article titled: “Roka Bioscience Reports Second Quarter 2016 Financial Results” with publication date: August 05, 2016.
ROKA Company Profile
Roka Bioscience, Inc., incorporated on September 3, 2009, is a molecular diagnostics company. The Firm is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Firm offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture assays, immunochemical assays and molecular assays. The Firm sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing instrument designed to reduce labor costs and operator error in foodborne pathogen testing laboratories. The Atlas instrument is a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.